Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.

Kirstin Perdrizet,Tracy L. Stockley,J. Law,Muqdas Shabir,Tong Zhang,Lisa W. Le,Anthea Lau,Ming-Sound Tsao,Prodipto Pal,Michael Cabanero,Hyang Mi Ko,Joerg Schwock,Suzanne Kamel-Reid,Geoffrey Liu,Adrian G. Sacher,Penelope Ann Bradbury,Frances A. Shepherd,Natasha B. Leighl

Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.

2019

Kirstin Perdrizet
Tracy L. Stockley
J. Law
Muqdas Shabir
Tong Zhang
Lisa W. Le
Anthea Lau
Ming-Sound Tsao
Prodipto Pal
Michael Cabanero
Hyang Mi Ko
Joerg Schwock
Suzanne Kamel-Reid
Geoffrey Liu
Adrian G. Sacher
Penelope Ann Bradbury
Frances A. Shepherd
Natasha B. Leighl

2620Background: Standard of care (SOC) molecular diagnostics for stage IV NSCLC patients in Ontario, Canada includes publicly reimbursed EGFR/ALK, and selected BRAF and ROS-1 testing. Other genomic...

Keywords:

Oncology
non-small cell lung cancer (NSCLC)
Pathology
DNA sequencing
Internal medicine
Health care
Medicine
stage iv
genomic sequencing
standard of care
Molecular diagnostics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations